Table 2 Characteristics at initiation of antiretroviral treatment (ART) and during follow-up (last visit) of HIV-infected adults in the three participating centers, IeDEA West Africa, December 2009 to December 2011
Characteristics | Total | Aconda-CePReF | CMSDS | CTA/CNHU | ||||
|---|---|---|---|---|---|---|---|---|
N = 978 | n = 570 | n = 198 | n = 210 | |||||
At ART initiation | ||||||||
Sex, woman, n (%) | 692 | (71) | 420 | (74) | 140 | (71) | 119 | (57) |
Age (years), median (IQR) | 39 | (33–45) | 36 | (31–44) | 35 | (31–41) | 36 | (31–42) |
BMI (Kg/m2), median (IQR) | 20.1 | (17.9-22.7) | 19.7 | (17.6-22.2) | 20.8 | (18.7-23.7) | 21.0 | (18.8-24.6) |
CD4 (/mm3), number, median (IQR) | 137 | (59–239) | 136 | (61–249) | 157 | (60–242) | 108 | (47–180) |
Antiretroviral treatment, n (%) | ||||||||
2NRTIs + 1NNRTIs | 678 | (69.3) | 381 | (66.8) | 135 | (68,2) | 162 | (77,1) |
2NRTIs + 1PI | 87 | (9) | 48 | (8) | 26 | (13) | 13 | (6) |
Other | 213 | (22) | 141 | (25) | 37 | (19) | 35 | (17) |
Follow-up data* | ||||||||
Total follow-up (months), median (IQR) | 34.9 | (16.3-67.1) | 35.5 | (14.6-66.2) | 35.0 | (18.2-54.1) | 33.5 | (16.9-76.6) |
Follow-up until event (months), median (IQR) ((I(((IQR) | 23.1 | (3.4-54.6) | 24.6 | (2.6-55.5) | 18.7 | (3.5-43.1) | 23.2 | (5.8-66.2) |
CD4 cell/mm3 median (IQR) | 269 | (103–467) | 267 | (102–453) | 289 | (124–517) | 237 | (73–468) |
WHO stage, n (%) | ||||||||
Stage 1 or 2 | 167 | (17.1) | 29 | (5) | 119 | (60.2) | 19 | (9) |
Stage 3 | 242 | (24.7) | 128 | (22) | 48 | (24.2) | 66 | (31) |
Stage 4 | 80 | (8.2) | 41 | (7) | 27 | (13.6) | 12 | (6) |